40 Participants NeededMy employer runs this trial

DPP System for Type 1 Diabetes

(SMART02 Trial)

KV
ES
Overseen ByEden Stein, B.Sc, M.Sc, MBA
Age: 18+
Sex: Any
Trial Phase: Phase < 1
Sponsor: ClinSurge Research
Must be taking: Insulin
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This research study is testing an investigational dual-port insulin patch pump that integrates a continuous glucose monitor (CGM) in adults with type 1 diabetes. The goal of the study is to better understand how insulin delivery near a CGM sensor affects glucose readings and to collect data to support development of a combined insulin pump and CGM system.

People with type 1 diabetes require lifelong insulin therapy. Many use insulin pumps and CGMs, but these systems usually involve wearing multiple devices at different body sites. Managing several devices can increase treatment burden and may contribute to skin irritation, device failures, and challenges with glucose control.

This study is conducted in two in-patient parts. In Part A, participants will wear three investigational devices at the same time while glucose levels are closely monitored using laboratory blood tests and a commercial CGM. This part of the study is designed to measure how basal and bolus insulin delivery near the CGM sensor affects sensor accuracy and how quickly the sensor signal recovers after insulin delivery.

In Part B, participants will wear one investigational device while trained study staff use CGM information from the integrated sensor to guide insulin delivery recommendations generated by an automated glucose control algorithm. Insulin delivery decisions will be closely supervised, and glucose levels will be frequently monitored.

Participants will stay at the clinical research center for short, controlled study visits. Safety will be monitored throughout the study, with predefined procedures for treating low or high blood sugar. The information collected will be used to support further development of an integrated insulin pump and CGM system for people with type 1 diabetes.

Are You a Good Fit for This Trial?

This trial is for adults (18+) with type 1 diabetes for at least a year, who have been using insulin therapy (pump or injections) for at least 3 months and take between 30-100 units of insulin daily. People can't join if they have serious health issues, recent severe low blood sugar or diabetic ketoacidosis, are pregnant, or can't safely wear the devices.

Inclusion Criteria

I have used daily insulin injections or a pump for at least 3 months.
I am 18 years old or older.
I have had type 1 diabetes for at least 12 months.
See 5 more

Exclusion Criteria

Serious medical illness likely to interfere with study participation or ability to complete the trial by investigator judgment
Failure to comply with study protocol or team recommendations
Insufficient abdominal surface area to support wearing of three DPP systems in Part A
See 8 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Part A: Sensor Characterization

Participants undergo a 1.5-day in-patient stay using the DPP System to assess sensor response to basal and bolus insulin delivery.

1.5 days
1 in-patient visit

Part B: Automated Glycaemic Control Feasibility

Participants undergo a 2.5-day in-patient stay using the DPP System and an automated glycaemic control algorithm to evaluate glucose control.

2.5 days
1 in-patient visit

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • DPP System (Insulin Pump and Continuous Glucose Monitoring Platform)

Trial Overview

The study tests a new dual-port insulin patch pump that combines an insulin pump and continuous glucose monitor in one device. Participants will use either one or three of these investigational devices during short hospital stays to see how well the system works and affects glucose readings.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Sensor Characterization and Automated Glycaemic ControlExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

ClinSurge Research

Lead Sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre

Collaborator

Trials
476
Recruited
170,000+

PharmaSens AG, Biel/Bienne Switzerland

Collaborator